Literature DB >> 1105471

A comparison of rifampicin, ethambutol or PAS in short-term monotherapy in pretreated cavitary pulmonary tuberculosis.

.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1105471     DOI: 10.1007/bf02096334

Source DB:  PubMed          Journal:  Pneumonologie        ISSN: 0033-4073


× No keyword cloud information.
  33 in total

Review 1.  [Current status of the antitubercular chemotherapy].

Authors:  K L Radenbach
Journal:  Internist (Berl)       Date:  1973-03       Impact factor: 0.743

Review 2.  [Chemoprevention and preventive chemotherapy of tuberculosis in adulthood (Review)].

Authors:  K L Radenbach
Journal:  Prax Pneumol       Date:  1974-12

3.  Rifampicin, ethambutol and capreomycin in pulmonary tuberculosis, previously treated with both first and second line drugs: the results of 2 years chemotherapy.

Authors:  M Aquinas; K M Citron
Journal:  Tubercle       Date:  1972-09

4.  Rifampin and ethambutol in the retreatment of advanced pulmonary tuberculosis.

Authors:  A Gyselen; L Verbist; J Cosemans; L M Lacquet; E Vandenbergh
Journal:  Am Rev Respir Dis       Date:  1968-12

5.  [Chemoprevention and preventive chemotherapy of tuberculosis].

Authors:  K Bartmann
Journal:  Internist (Berl)       Date:  1973-03       Impact factor: 0.743

6.  Rifampin: its role in the treatment of tuberculosis.

Authors:  A N Houk
Journal:  Chest       Date:  1972-06       Impact factor: 9.410

7.  [Difficulties in ethambutol dosage].

Authors:  I Schütz
Journal:  Pneumonologie       Date:  1971

Review 8.  [Experimental chemotherapy of tuberculosis].

Authors:  A Krebs
Journal:  Z Erkr Atmungsorgane Folia Bronchol       Date:  1969

9.  Preliminary observations of ethambutol in pulmonary tuberculosis.

Authors:  G DeSimoni
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

10.  Comparison of ethambutol-INH versus INH-PAS in original treatment of pulmonary tuberculosis.

Authors:  I D Bobrowitz
Journal:  Ann N Y Acad Sci       Date:  1966-04-20       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.